Effect of proton pump inhibitor use on Helicobacter pylori positivity and atrial fibrillation
Authors Atay K, Kaya O
Received 16 May 2015
Accepted for publication 19 May 2015
Published 29 June 2015 Volume 2015:10 Pages 1069—1070
Checked for plagiarism Yes
Kadri Atay,1 Omer Kaya2
1Istanbul University, Cerrahpasa School of Medicine, Division of Gastroenterology, 2Medipol University, Department of Internal Medicine, Istanbul, Turkey
We read with interest the report by Wang et al regarding the association between Helicobacter pylori infection and atrial fibrillation.1
Read the original article
We read with interest the report by Wang et al regarding the association between Helicobacter pylori infection and atrial fibrillation.1 One of our concerns about this well designed study is the lack of reporting of proton pump inhibitor (PPI) use in the patients and controls. It is well known that use of PPIs influences the results of some tests for H. pylori, including the urea breath test, which the authors used in their study. Notably, the frequency of H. pylori antibody positivity was similar between all three groups while H. pylori infection seems to be significantly more common in subjects with long-standing atrial fibrillation. More frequent use of PPIs may potentially explain the lower frequency of H. pylori positivity in the control group and short-term atrial fibrillation group. Further, there are some recent reports indicating a protective effect of PPIs on the risk of atrial fibrillation, especially in people with gastroesophageal reflux disease.2 In conclusion, use of PPIs may have influenced some of the test results in this study, including the risk of atrial fibrillation.
The authors have no conflicts of interest to disclose in relation to this communication.
Wang DZ, Chen W, Yang S, et al. Helicobacter pylori infection in Chinese patients with atrial fibrillation. Clin Interv Aging. 2015;10:813–819.
Roman C, Bruley des Varannes S, Muresan L, Picos A, Dumitrascu DL. Atrial fibrillation in patients with gastroesophageal reflux disease: a comprehensive review. World J Gastroenterol. 2014;20:9592–9599.
1Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, 2Department of Ultrasonography, Beijing Tiantan Hospital, Capital Medical University, 3Department of Cardiology, Beijing Mentougou District Hospital, Beijing, People’s Republic of China
Correspondence: De-Zhao Wang, Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, No 6, Tiantan Xili, Dongcheng District, Beijing 100050, People’s Republic of China, Tel +86 10 6709 6577, Email firstname.lastname@example.org
We are very glad to respond to the enquiry from Kadri Atay and Omer Kaya about use of PPIs in our subject. This study was a retrospective, cross-sectional analysis from a single center, and patients with gastrointestinal disease and those on PPI therapy before recruitment were excluded from the study.
The authors report no conflicts of interest in this communication.
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Clinical Interventions in Aging ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Clinical Interventions in Aging editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]